Cargando…

The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review

BACKGROUND: Hemophilia carriers (HCs) face specific psychosocial challenges related to pregnancy, caused by their inherited bleeding disorder. Optimal support from healthcare providers can only be realized by exploring medical and psychological healthcare requirements. OBJECTIVE: To review all publi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Punt, Marieke C., Aalders, Tanja H., Bloemenkamp, Kitty W. M., Driessens, Mariette H. E., Fischer, Kathelijn, Schrijvers, Marlies H., van Galen, Karin P. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	HAEMOSTASIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383726/ https://www.ncbi.nlm.nih.gov/pubmed/32271985 http://dx.doi.org/10.1111/jth.14825

Ejemplares similares

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

A qualitative study on the experiences of haemophilia carriers before, during and after pregnancy
por: Punt, Marieke C., et al.
Publicado: (2021)

Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021)

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
por: Hassan, Shermarke, et al.
Publicado: (2021)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Genetic analysis of carrier status in female members of Japanese hemophilia families
por: Shinozawa, Keiko, et al.
Publicado: (2021)

Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
por: Hassan, Shermarke, et al.
Publicado: (2020)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Prevalence, burden and treatment effects of vaginal bleeding in women with (suspected) congenital platelet disorders throughout life: a cross‐sectional study
por: Punt, Marieke C., et al.
Publicado: (2021)

Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate‐severe hemophilia A
por: Funk, Sharon M., et al.
Publicado: (2019)

Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database
por: Versloot, Olav, et al.
Publicado: (2021)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort
por: Pasi, K. John, et al.
Publicado: (2021)

Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A
por: Kaneda, Makoto, et al.
Publicado: (2021)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
por: Atiq, Ferdows, et al.
Publicado: (2021)

Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021)

SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders
por: Cnossen, Marjon H., et al.
Publicado: (2022)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries
por: Usuba, Koyo, et al.
Publicado: (2019)

Menstrual problems in chronic immune thrombocytopenia: A monthly challenge ‐ a cohort study and review
por: van Dijk, Wobke E. M., et al.
Publicado: (2022)

FVIII inhibitors display FV‐neutralizing activity in the prothrombin time assay
por: Arsiccio, Andrea, et al.
Publicado: (2021)

The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice
por: Buijs, Jeroen T., et al.
Publicado: (2019)

Full‐length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients
por: Coleman, Julia R., et al.
Publicado: (2022)

A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys
por: Lauritzen, Brian, et al.
Publicado: (2022)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

A tailored intervention for illness acceptance improves adherence and quality of life in adults with haemophilia using prophylaxis
por: Hoefnagels, Johanna Wilhelmina, et al.
Publicado: (2021)

Treatment of patients with rare bleeding disorders in the Netherlands: Real‐life data from the RBiN study
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2022)

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts
por: Chun, Haarin, et al.
Publicado: (2022)

Differences in thrombin and plasmin generation potential between East African and Western European adults: The role of genetic and non‐genetic factors
por: Temba, Godfrey S., et al.
Publicado: (2022)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Blockade of the costimulatory CD28‐B7 family signal axis enables repeated application of AAV8 gene vectors
por: Frentsch, Marco, et al.
Publicado: (2020)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

A novel assay for studying the involvement of blood cells in whole blood thrombin generation
por: Wan, Jun, et al.
Publicado: (2020)

Coagulopathy signature precedes and predicts severity of end‐organ heat stroke pathology in a mouse model
por: Proctor, Elizabeth A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qd2ocm10tlr4v85emauf2t31jg